ReviewLife (Basel, Switzerland)2025
The Role of Renalase in Cardiovascular Disease: A Comprehensive Review of Its Molecular Biology, Genetic Associations, and Clinical Significance.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Renalase, a flavin adenine dinucleotide (FAD)-dependent enzyme/hormone, has emerged as a molecule of significant interest in cardiovascular medicine since its discovery nearly two decades ago. Initially proposed as a catecholamine-degrading enzyme crucial for blood pressure regulation, its functional repertoire has expanded to include potential α-NAD(P)H oxidase/anomerase activity and roles as a signalling cytokine. This review synthesises the current understanding of renalase, encompassing its fundamental biology, intricate gene regulation by transcriptional factors, microRNAs, and physiological stimuli, and its implications in cardiovascular health and disease. A central focus is the critical appraisal of circulating renalase as a clinical biomarker. We critically evaluate findings from preclinical animal and cellular models related to atherosclerosis, heart failure, and blood pressure control. Furthermore, this review examines the extensive literature on RNLS gene polymorphisms and their associations with human cardiovascular phenotypes, alongside the complex and often context-dependent data regarding circulating renalase levels as a potential clinical biomarker in conditions such as hypertension, coronary artery disease, atrial fibrillation, and heart failure. While renalase shows context-specific promise, its multifaceted biology and the current methodological disparities limit its immediate clinical application. This review concludes by outlining a clear path forward, emphasising the need for standardised research and mechanistic studies to unlock the true diagnostic and therapeutic potential of renalase in CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.